Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07437105 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT07437105: Recruiting Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT07437105 is a Phase 1 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 128 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07437105, a Phase 1 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
Interventions
- DRUG Placebo
- DRUG VX-272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2027-03-23 |
| Phase | Phase 1 |
What NCT07437105 shows while recruiting
NCT07437105 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (113% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07437105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07437105 about?
NCT07437105 is a clinical study titled "Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants". The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272.
What is the current status of trial NCT07437105?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2026-02-25. Estimated completion is 2027-03-23.
What interventions are being tested in trial NCT07437105?
The interventions under investigation include: Placebo (DRUG), VX-272 (DRUG).
Who is sponsoring clinical trial NCT07437105?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07437105's enrollment target sits among peer trials
128 452nd of 2000 higher than 1,542 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI